DELTA-actitoxin-Aeq1a Antibody

What is DELTA-actitoxin-Aeq1a and what is its structural composition?

DELTA-actitoxin-Aeq1a is a pore-forming protein toxin isolated from the sea anemone Actinia equina. The protein has a sequence length of 214 amino acids and its structure has been computationally modeled using AlphaFold . The model shows a confident structure prediction with a global pLDDT (predicted Local Distance Difference Test) score of 88.38, indicating high reliability of the structural model . The protein belongs to the actinoporin family, which are known to create pores in cell membranes, leading to cell lysis. The structural model was released in the AlphaFold DB on December 9, 2021, and last modified on September 30, 2022 .

How are DELTA-actitoxin-Aeq1a antibodies typically produced for research purposes?

DELTA-actitoxin-Aeq1a antibodies are typically produced through immunization protocols using either the native toxin isolated from Actinia equina or recombinant versions of the protein. For recombinant approaches, the toxin can be expressed in E. coli expression systems with tags such as N-terminal His-SUMO tags to facilitate purification . The recombinant protein serves as an immunogen for antibody production in host animals such as rabbits, mice, or goats. Polyclonal antibodies can be harvested from serum, while monoclonal antibodies require hybridoma technology following B-cell isolation from immunized animals. The antibodies are then purified using affinity chromatography techniques to ensure specificity for research applications.

What are the validated applications for DELTA-actitoxin-Aeq1a antibodies in research?

DELTA-actitoxin-Aeq1a antibodies have several validated research applications:

• Detection and quantification: Western blotting, ELISA, and immunohistochemistry for identifying the presence and concentration of the toxin in biological samples

• Localization studies: Immunofluorescence microscopy to determine cellular and subcellular distribution of the toxin

• Neutralization assays: Evaluating the ability of antibodies to inhibit the hemolytic and cytotoxic effects of the toxin

• Structure-function analysis: Epitope mapping to identify functional domains within the toxin

• Cross-reactivity studies: Investigating immunological relationships between DELTA-actitoxin-Aeq1a and other actinoporins from different sea anemone species

What is the difference between polyclonal and monoclonal antibodies against DELTA-actitoxin-Aeq1a?

How does the molecular structure of DELTA-actitoxin-Aeq1a influence epitope selection for antibody development?

The molecular structure of DELTA-actitoxin-Aeq1a significantly impacts epitope selection for developing effective antibodies. The AlphaFold model of the protein indicates varying levels of structural confidence across different regions, with pLDDT scores ranging from confident (70-90) to very high (>90) . When selecting epitopes for antibody development, researchers should preferentially target highly exposed regions with strong confidence scores to ensure antibody accessibility and binding reliability.

What are the challenges in developing antibodies that can distinguish between DELTA-actitoxin-Aeq1a and similar actinoporins from other sea anemones?

Developing antibodies with high specificity for DELTA-actitoxin-Aeq1a presents several significant challenges:

• Sequence homology: Actinoporins from different sea anemone species share considerable sequence homology. For example, research has identified similar actinoporins like DELTA-actitoxin-Aas1a that share structural features with DELTA-actitoxin-Aeq1a .

• Conserved functional domains: The pore-forming regions and membrane-binding domains are often highly conserved among actinoporins, making it difficult to develop antibodies that target these functionally important regions without cross-reactivity.

• Conformational epitopes: Many distinguishing epitopes may be conformational rather than linear, requiring antibodies that recognize the three-dimensional structure rather than just the primary sequence.

• Limited structural data: While computational models exist , the lack of experimentally verified structural data (such as X-ray crystallography or cryo-EM structures) makes precise epitope mapping challenging.

To overcome these challenges, researchers can employ strategies such as:

• Targeting the most variable regions between different actinoporins

• Using subtractive screening approaches to eliminate cross-reactive antibody clones

• Developing panels of monoclonal antibodies that, in combination, provide specificity

• Employing phage display technology to select high-affinity, highly specific antibody fragments

How can DELTA-actitoxin-Aeq1a antibodies be used to study the mechanism of pore formation in cell membranes?

DELTA-actitoxin-Aeq1a antibodies provide powerful tools for investigating the mechanism of pore formation in cell membranes. These antibodies can be utilized in multiple experimental approaches:

• Time-course immunofluorescence studies: Using fluorescently labeled antibodies to track the temporal sequence of toxin binding, oligomerization, and pore formation in real-time on cell membranes.

• Epitope-specific blocking experiments: Antibodies targeting different structural domains can help determine which regions are essential for membrane binding versus pore formation. This approach can separate the initial membrane attachment step from subsequent oligomerization and pore insertion.

• Correlative microscopy: Combining electron microscopy with immunogold-labeled antibodies to visualize the precise structure of pore complexes at different stages of formation.

• Single-molecule tracking: Using Fab fragments labeled with quantum dots to track individual toxin molecules during the pore formation process without interfering with oligomerization.

• Antibody-based prevention of hemolysis: Research has shown that actinoporins like DELTA-actitoxin-Aeq1a exhibit hemolytic activity against mammalian erythrocytes, with varying HU50 values depending on the species (sheep: 10.7 ± 0.2 μg, goat: 13.2 ± 0.3 μg, rabbit: 34.7 ± 0.5 μg, and human: 25.6 ± 0.6 μg) . Antibodies can be used to neutralize this activity, providing insights into the mechanism of pore formation.

What are the most effective experimental controls when validating DELTA-actitoxin-Aeq1a antibodies for research use?

When validating DELTA-actitoxin-Aeq1a antibodies, implementing rigorous controls is essential to ensure reliable and reproducible results:

For recombinant DELTA-actitoxin-Aeq1a protein, additional controls should include testing the antibody against expression tag proteins (His-SUMO tags) alone to ensure specificity for the toxin rather than the purification tags .

What is the optimal immunization protocol for generating high-affinity antibodies against DELTA-actitoxin-Aeq1a?

The optimal immunization protocol for generating high-affinity antibodies against DELTA-actitoxin-Aeq1a involves careful consideration of several factors:

Antigen preparation:

• Use highly purified recombinant DELTA-actitoxin-Aeq1a (>85% purity as determined by SDS-PAGE)

• Recombinant expression in E. coli with N-terminal His-SUMO tags facilitates purification while maintaining proper folding

• Consider using the full-length 214 amino acid protein rather than fragments to preserve conformational epitopes

Immunization schedule:

• Initial immunization: 50-100 μg of purified protein emulsified in complete Freund's adjuvant, administered subcutaneously at multiple sites

• Booster immunizations: 25-50 μg protein in incomplete Freund's adjuvant at 2, 4, and 6 weeks after initial immunization

• Final boost: 25 μg protein in PBS administered intravenously 3-4 days before harvesting antibody-producing cells (for monoclonal antibody production) or serum collection (for polyclonal antibodies)

Host selection considerations:

• Rabbits: Preferred for polyclonal antibody production due to higher serum volumes

• Mice (BALB/c): Optimal for subsequent hybridoma development for monoclonal antibodies

• Guinea pigs or chickens: Alternative hosts if the protein shows low immunogenicity in conventional hosts

Adjuvant alternatives:
If Freund's adjuvant is contraindicated due to animal welfare concerns, consider alum, RIBI, or TiterMax Gold as effective alternatives that induce strong immune responses with reduced adverse effects.

What purification methods yield the highest specificity antibodies against DELTA-actitoxin-Aeq1a?

To obtain the highest specificity antibodies against DELTA-actitoxin-Aeq1a, a multi-step purification process is recommended:

• Initial IgG isolation from serum or hybridoma supernatant:

  • Protein A/G affinity chromatography for most mammalian IgG subclasses

  • Ammonium sulfate precipitation (35-45% saturation) as a preliminary concentration step

• Antigen-specific affinity purification:

  • Prepare affinity column by coupling purified recombinant DELTA-actitoxin-Aeq1a to activated support (CNBr-activated Sepharose or NHS-activated agarose)

  • For proteins expressed with His-SUMO tags, consider removing tags before coupling to avoid antibodies targeting the tags

  • Apply the IgG fraction to the affinity column at physiological pH

  • Wash extensively to remove non-specific antibodies

  • Elute specific antibodies using gentle conditions (0.1M glycine-HCl, pH 2.5-3.0) followed by immediate neutralization

• Negative selection to remove cross-reactive antibodies:

  • Pass the affinity-purified antibodies through columns containing immobilized related actinoporins

  • This subtraction step removes antibodies that recognize conserved epitopes among actinoporins

• Quality control assessments:

  • ELISA titration against DELTA-actitoxin-Aeq1a vs. related toxins to confirm specificity

  • Western blot against recombinant protein and native sea anemone extracts

  • Functional neutralization assay to confirm recognition of the native conformation

This comprehensive purification approach typically yields antibody preparations with >95% specificity for DELTA-actitoxin-Aeq1a compared to related actinoporins.

How can researchers validate the specificity of DELTA-actitoxin-Aeq1a antibodies in complex biological samples?

Validating antibody specificity in complex biological samples is crucial for reliable research outcomes. For DELTA-actitoxin-Aeq1a antibodies, a multi-faceted validation approach is recommended:

Immunoblotting validation:

• Prepare a panel of samples including:

  • Purified recombinant DELTA-actitoxin-Aeq1a (positive control)

  • Tissue extracts from Actinia equina (source organism)

  • Extracts from related sea anemone species containing different actinoporins

  • Negative control tissues not expressing actinoporins

• Perform Western blot analysis using standardized conditions

  • The antibody should detect a single band at the expected molecular weight (~18.7-29 kDa, depending on the specific form)

  • If using recombinant protein with tags, account for the altered molecular weight (approximately 50.3 kDa for His-SUMO tagged versions)

Immunoprecipitation followed by mass spectrometry:

• Immunoprecipitate proteins from Actinia equina extracts using the antibody

• Analyze precipitated proteins by mass spectrometry

• Verify that DELTA-actitoxin-Aeq1a is the predominant protein identified

• This approach has been successful in identifying actinoporins in related research, with up to 32% coverage obtained for similar toxins

Proximity ligation assay (PLA):
Combine the test antibody with a validated antibody targeting a different epitope on DELTA-actitoxin-Aeq1a. True positive signals will only occur when both antibodies bind in close proximity to the same protein.

Functional neutralization:
Assess the antibody's ability to neutralize the hemolytic activity of DELTA-actitoxin-Aeq1a. The toxin demonstrates hemolytic activity against erythrocytes from various species with different HU50 values. A specific antibody should inhibit this activity in a dose-dependent manner .

What are the best practices for storing DELTA-actitoxin-Aeq1a antibodies to maintain long-term activity?

Proper storage is essential for maintaining antibody activity and specificity over time. For DELTA-actitoxin-Aeq1a antibodies, the following best practices are recommended:

Short-term storage (up to 1 month):

• Store at 4°C in PBS (pH 7.2-7.4) with 0.02% sodium azide as a preservative

• Add stabilizing proteins such as 1% BSA or 5% glycerol to prevent adsorption to container surfaces

• Avoid repeated freeze-thaw cycles that can lead to antibody denaturation and aggregation

Long-term storage (months to years):

• Aliquot antibodies into small volumes (20-50 μL) to minimize freeze-thaw cycles

• Store at -20°C for up to 6 months or -80°C for extended periods (1-2 years)

• For lyophilized formats, storage at -20°C can extend shelf life to 12 months or more

• Reconstitute lyophilized antibodies in recommended buffers such as Tris/PBS with 6% Trehalose (pH 8.0)

Alternative preservation methods:

• Addition of cryoprotectants: 50% glycerol solutions allow storage at -20°C without freezing solid, reducing damage from freeze-thaw cycles

• Lyophilization: For bulk storage, lyophilization in the presence of stabilizers (trehalose, sucrose) can extend shelf life significantly

Quality control for stored antibodies:

• Periodically test activity using ELISA against purified DELTA-actitoxin-Aeq1a

• Monitor for aggregation using dynamic light scattering or size-exclusion chromatography

• Check for contamination and sterility, especially for antibodies stored at 4°C

Shipping considerations:

• Ship antibodies on blue ice for short distances/durations

• For international shipping, use dry ice or specialized cold-chain packaging

Following these guidelines will help maintain antibody quality and research reproducibility when working with DELTA-actitoxin-Aeq1a antibodies.

How can DELTA-actitoxin-Aeq1a antibodies be used to study the evolutionary relationships between different sea anemone toxins?

DELTA-actitoxin-Aeq1a antibodies provide powerful tools for investigating evolutionary relationships between sea anemone toxins through several methodological approaches:

• Cross-reactivity profiling:

  • Systematic testing of antibody reactivity against actinoporins from diverse sea anemone species

  • Creation of cross-reactivity heat maps that visualize antigenic relationships

  • These immunological relationships often correlate with evolutionary proximity

• Epitope conservation analysis:

  • Using epitope-specific monoclonal antibodies to map conserved vs. divergent regions across actinoporins

  • Correlating antibody binding patterns with phylogenetic relationships derived from sequence data

  • Identifying functionally constrained epitopes that remain conserved despite sequence divergence

• Immunohistochemical localization in different species:

  • Comparative localization studies across sea anemone species to determine if toxin expression patterns reflect evolutionary relationships

  • Correlation of toxin distribution with specialized structures and ecological niches

• Quantitative immunoassays for comparative toxicology:

  • Developing standardized ELISAs to quantify different actinoporins across species

  • Correlating toxin abundance with evolutionary adaptations and predatory strategies

This immunological approach complements traditional phylogenetic analyses based on sequence data. For example, researchers have already identified similarities between DELTA-actitoxin-Aeq1a from Actinia equina and DELTA-actitoxin-Aas1a from other sea anemones, with up to 32% sequence coverage in comparative studies . Antibody cross-reactivity studies can reveal functional and structural conservation that may not be immediately apparent from sequence analysis alone.

What techniques can be used to couple DELTA-actitoxin-Aeq1a antibodies with imaging modalities for tracking the toxin in cellular systems?

Advanced imaging applications of DELTA-actitoxin-Aeq1a antibodies require specialized coupling techniques to maintain antibody functionality while enabling high-resolution visualization:

Fluorescent labeling strategies:

• Direct conjugation with fluorophores:

  • Small organic dyes (Alexa Fluor, Cy3/Cy5, FITC) can be conjugated to purified antibodies using NHS-ester chemistry

  • Optimal dye-to-antibody ratio (DAR) of 3-4 molecules per antibody balances brightness with potential interference

  • Quantum dots offer exceptional brightness and photostability for long-term tracking experiments

• Enzymatic labeling approaches:

  • Site-specific labeling using sortase A or transglutaminase for controlled orientation

  • Enzymatic coupling preserves antigen-binding regions and improves functional retention

• Fragment-based imaging:

  • Generation of Fab or scFv fragments against DELTA-actitoxin-Aeq1a for reduced size and better tissue penetration

  • Smaller fragments minimize interference with toxin function during live imaging

Advanced microscopy applications:

• Super-resolution techniques:

  • STORM/PALM microscopy using photoswitchable dye-conjugated antibodies to visualize nanoscale distribution of toxins on cell membranes

  • Expansion microscopy where labeled specimens are physically expanded in hydrogels to achieve super-resolution with standard microscopes

• Live-cell imaging:

  • Cell-permeable fluorescently labeled nanobodies for tracking internalized toxin

  • SNAP/CLIP-tag fusions to toxins recognized by specialized antibodies for pulse-chase experiments

• Correlative light-electron microscopy (CLEM):

  • Immunogold labeling using antibodies conjugated to gold nanoparticles (5-15 nm)

  • Proteins like DELTA-actitoxin-Aeq1a can be simultaneously visualized by fluorescence and electron microscopy for structural context

• Functional imaging:

  • Biosensor approaches using antibody-based FRET pairs to detect conformational changes during pore formation

  • Coupling antibody labeling with calcium imaging to correlate toxin binding with functional pore formation

These techniques enable researchers to track DELTA-actitoxin-Aeq1a from initial cell binding through pore formation and potential cellular internalization with unprecedented spatial and temporal resolution.

How can epitope mapping of DELTA-actitoxin-Aeq1a antibodies inform structure-function studies of the toxin?

Epitope mapping of antibodies against DELTA-actitoxin-Aeq1a provides critical insights into the toxin's structure-function relationships through several methodological approaches:

Comprehensive epitope mapping strategies:

• Peptide array mapping:

  • Overlapping peptides (15-20 amino acids) spanning the entire 214-amino acid sequence of DELTA-actitoxin-Aeq1a

  • Identifies linear epitopes recognized by antibodies

  • Correlation with functional domains based on the AlphaFold structural model (pLDDT score: 88.38)

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Compares deuterium uptake patterns in the presence and absence of antibody binding

  • Identifies conformational epitopes that may not be detected by linear peptide approaches

  • Particularly valuable for DELTA-actitoxin-Aeq1a where functional activity depends on tertiary structure

• Alanine scanning mutagenesis:

  • Systematic replacement of residues with alanine to identify critical binding determinants

  • Correlation of epitope residues with functional effects on hemolytic activity

  • The hemolytic activity against different mammalian erythrocytes (HU50 values ranging from 10.7 ± 0.2 μg for sheep to 34.7 ± 0.5 μg for rabbit) can be used as a functional readout

Structure-function applications of epitope mapping:

• Identification of functional domains:

  • Antibodies recognizing epitopes that neutralize cytolytic activity (measured by LDH release assays) help identify the pore-forming domains

  • Antibodies that block membrane binding without affecting oligomerization help distinguish these functional regions

• Conformational dynamics insights:

  • Epitope accessibility studies under different conditions reveal conformational changes during pore formation

  • Antibodies as probes for detecting intermediate states in the pore formation process

• Rational design of inhibitors:

  • Identified epitopes that neutralize toxin activity can guide the design of peptide-based or small molecule inhibitors

  • Structure-based vaccine design focusing on protective epitopes

• Cross-species comparison:

  • Mapping conserved vs. variable epitopes across actinoporins helps understand evolutionary adaptations

  • Correlation of epitope conservation with functional importance across the actinoporin family

By combining epitope mapping data with the computational structure model (pLDDT score: 88.38) and functional assays measuring hemolytic and cytotoxic activities , researchers can develop a comprehensive understanding of structure-function relationships in DELTA-actitoxin-Aeq1a.

What are the methodological considerations for using DELTA-actitoxin-Aeq1a antibodies in neutralization assays?

Developing robust neutralization assays using DELTA-actitoxin-Aeq1a antibodies requires careful methodological considerations to ensure reliable and reproducible results:

Assay design and optimization:

• Selection of appropriate cellular models:

  • Human lung carcinoma epithelial cells (A549) have demonstrated sensitivity to actinoporins, with IC50 values around 1.84 ± 0.40 μg/mL in trypan blue cytotoxicity assays

  • Erythrocytes from different mammalian species (sheep, goat, human, rabbit) with varying sensitivities can be used for hemolysis assays

  • The choice of cell type should align with the specific research question (membrane composition, receptor expression)

• Quantitative readouts:

  • Hemolysis assays measuring released hemoglobin (spectrophotometric measurement at 540 nm)

  • Lactate dehydrogenase (LDH) release assays for measuring cytotoxicity in nucleated cells

  • Cell viability assays (MTT, CellTiter-Glo) for measuring cell survival

  • Membrane potential dyes for real-time monitoring of pore formation

Neutralization protocol optimization:

Data analysis and interpretation:

• Dose-response relationships:

  • Calculate IC50 values (antibody concentration providing 50% neutralization)

  • Determine neutralization potency relative to positive control inhibitors

  • Compare complete neutralization vs. partial protection

• Mechanism of neutralization:

  • Distinguish between antibodies that prevent membrane binding versus those that inhibit pore formation after binding

  • Use flow cytometry with fluorescently labeled toxin to determine if antibodies prevent cell binding

  • Employ osmoprotectants of different sizes (PEG) to determine if antibodies affect pore size rather than completely preventing formation

These methodological considerations ensure that neutralization assays provide meaningful insights into both the protective potential of DELTA-actitoxin-Aeq1a antibodies and the mechanism by which they interfere with toxin activity.

How might structural information from the AlphaFold model of DELTA-actitoxin-Aeq1a guide antibody development for research and therapeutic applications?

The AlphaFold computational model of DELTA-actitoxin-Aeq1a provides valuable structural insights that can strategically guide antibody development for both research and therapeutic applications:

Structure-guided epitope selection:

The AlphaFold model of DELTA-actitoxin-Aeq1a has a global pLDDT score of 88.38, indicating a confident prediction of the protein's structure . This model reveals regions with varying structural confidence:

• Very high confidence regions (pLDDT > 90): Likely represent stable structural elements

• Confident regions (70 < pLDDT ≤ 90): Well-defined but potentially with some flexibility

• Lower confidence regions (pLDDT ≤ 70): May represent flexible loops or disordered segments

For antibody development, researchers can:

• Target highly exposed epitopes in high-confidence regions for detection antibodies

• Focus on functional domains predicted by structural analysis for neutralizing antibodies

• Avoid regions with very low confidence scores as they may not represent stable epitopes in the native protein

Application-specific antibody engineering:

• Research antibodies:

  • Design conformation-specific antibodies that recognize the native fold of the 214-amino acid protein

  • Develop antibodies against distinct structural domains to probe structure-function relationships

  • Create epitope-tagged versions for co-localization studies

• Therapeutic antibodies:

  • Target the membrane-binding interface to block the initial attachment step

  • Design antibodies against oligomerization interfaces to prevent pore assembly

  • Engineer bispecific antibodies that simultaneously target two critical epitopes

  • Consider humanization of promising neutralizing antibodies for potential clinical development

• Diagnostic applications:

  • Design antibody pairs targeting non-overlapping epitopes for sandwich immunoassays

  • Develop antibodies specific to DELTA-actitoxin-Aeq1a versus other actinoporins for selective detection

Computational antibody design:

The availability of the AlphaFold model enables computational approaches to antibody development:

• In silico epitope prediction to identify optimal target regions

• Molecular docking of candidate antibodies to predict binding efficacy

• Structure-based optimization of antibody complementarity-determining regions (CDRs)

• Virtual screening of antibody libraries against the toxin structure

This structure-guided approach represents a significant advance over traditional trial-and-error antibody development, potentially reducing development time and improving success rates for both research and therapeutic antibodies against DELTA-actitoxin-Aeq1a.

What are the prospects for developing DELTA-actitoxin-Aeq1a antibodies as research tools for comparative toxinology studies?

DELTA-actitoxin-Aeq1a antibodies hold significant potential as research tools for advancing comparative toxinology across several innovative applications:

Cross-species toxin profiling:

Antibodies against DELTA-actitoxin-Aeq1a can serve as molecular probes for analyzing related toxins across the Actiniidae family and beyond. With appropriate epitope selection targeting conserved regions, researchers can:

• Develop immunoassays for toxin quantification across diverse sea anemone species

• Create taxonomic profiles based on immunological cross-reactivity patterns

• Identify novel actinoporins in previously uncharacterized species

Comparative structure-function analysis:

The AlphaFold model of DELTA-actitoxin-Aeq1a with its pLDDT score of 88.38 provides a structural template against which other actinoporins can be compared. Antibodies recognizing specific structural motifs can:

• Probe conservation of functional domains across species

• Identify species-specific structural adaptations

• Correlate structural differences with variations in hemolytic potency observed in different species (e.g., sheep: HU50 = 10.7 ± 0.2 μg vs. rabbit: HU50 = 34.7 ± 0.5 μg)

Evolutionary toxinology applications:

• Phylogenetic immunoprofiling:

  • Correlation of antibody cross-reactivity patterns with evolutionary relationships

  • Development of antibody panels that can distinguish between toxins from different evolutionary lineages

  • Identification of convergently evolved toxin structures through epitope mapping

• Ecological and evolutionary context:

  • Investigation of toxin distribution patterns across geographical regions

  • Correlation of toxin variations with predator-prey relationships

  • Analysis of toxin adaptations in response to environmental pressures

Methodological innovations:

• Multiplexed detection platforms:

  • Development of antibody arrays for simultaneous detection of multiple actinoporins

  • Bead-based multiplex immunoassays for high-throughput toxin profiling

  • Next-generation proteomics approaches combining antibody-based enrichment with mass spectrometry

• Standardization efforts:

  • Creation of reference antibodies for interlaboratory standardization of actinoporin research

  • Development of calibrated immunoassays for absolute quantification across studies

  • Establishment of immunological standards for toxin identification and classification

These applications would significantly advance the field of comparative toxinology, providing new insights into the evolution, diversity, and functional adaptations of sea anemone toxins while establishing standardized tools for research across laboratories.